The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Zeebon is the largest diagnostics services provider in North-Eastern states
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
2022 is going to be the year of opportunities and innovations from the medical industry in India
Subscribe To Our Newsletter & Stay Updated
